[1]
Que Y, Hu C, Wan K, et al. Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Int Rev Immunol 2022; 41(2): 217-30.
[2]
Mangalmurti N, Hunter CA. Cytokine storms: Understanding COVID-19. Immunity 2020; 53(1): 19-25.
[3]
Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther 2021; 6(1): 255.
[4]
Dobosh B, Zandi K, Giraldo DM, et al. Baricitinib attenuates the pro-inflammatory phase of COVID-19 driven by lung-infiltrating monocytes. Cell Rep 2022; 39(11): 110945.
[5]
Hu T, Tang C, Stern S, Yang L, Du T. 17Alpha-hydroxyprogesterone caproate inhibits cytokine production via suppression of NF-kappaB activation. Front Pharmacol 2022; 13: 831315.
[6]
Karki R, Kanneganti TD. The ‘cytokine storm’: Molecular mechanisms and therapeutic prospects. Trends Immunol 2021; 42(8): 681-705.
[7]
Sagulkoo P, Plaimas K, Suratanee A, Colado Simao AN, Vissoci Reiche EM, Maes M. Immunopathogenesis and immunogenetic variants in COVID-19. Curr Pharm Des 2022; 28(22): 1780-97.
[8]
Batista Simoes JL, Sobierai LD, Pereira SM, Rodrigues Dos Santos MV, Bagatini MD. Therapeutic potential of P2X7 purinergic receptor modulation in the main organs affected by the COVID-19 cytokine storm. Curr Pharm Des 2022; 28(22): 1798-814.
[9]
Cure MC, Cure E. Prolonged NHE activation may be both cause and outcome of cytokine release syndrome in COVID-19. Curr Pharm Des 2022; 28(22): 1815-22.
Download PDF Flyer